LR004
LR004 is an EGFR monoclonal antibody, with a Kd of 2.80×10-9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
Human
LR004 (5.0 μg/mL) binds recombinant human EGFR antigen with moderate affinity, with a Kd of 2.80×10-9 M[1].
LR004 (0.023-50 μg/mL; 24 h initial incubation, followed by 96 h incubation with serum-containing medium) inhibits the proliferation of MDA-MB-468 human breast cancer cells with an EC50 of 2.278 μg/mL[1].
LR004 (0.001-1 μg·mL-1; 48 h) has weak in vitro cytotoxicity against human EGFR-positive tumor cells (KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, AsPC-1) and EGFR-negative Karpas 299 cells, with IC50 values >6 nM or >60 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468 human breast cancer cells
-
Concentration:0.023-50 μg/mL
-
Incubation Time:24 h (initial incubation); 96 h (incubation with serum-containing medium)
-
Result:Inhibited MDA-MB-468 cell proliferation with an EC50 of 2.278 μg/mL.
-
Cell Line:KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, AsPC-1, Karpas 299
-
Concentration:0.001-1 μg·mL-1
-
Incubation Time:48 h
-
Result:Had a weak inhibitory effect on cell viability, with IC50 values >6 nM for KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, and AsPC-1 cells, and IC50 >60 nM for Karpas 299 cells.
LR004 (15 mg/kg; i.v.; every 4 days; 6 total doses) exerts limited tumor growth suppression in A431 epidermoid carcinoma xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, 18-20 g, KYSE520 tumor cell xenograft)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; every 4 days; 4 total doses
-
Result:Achieved an average tumor volume of 1791 mm3 on day 44.
Induced a 13.8% tumor inhibition rate.
Showed no tumor regression.
Caused no body weight loss or mortality.
Detected no histopathological abnormalities in major organs.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, 18-20 g, A431 tumor cell xenograft)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; every 4 days; 6 total doses
-
Result:Achieved an average tumor volume of 399 mm3 on day 60.
Exhibited limited therapeutic activity compared to LR004-VC-MMAE groups.
Detected no histopathological abnormalities in major organs.
P00533-1
EGFR
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
SMILES
[LR004]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Zheng Y, et al. Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody. Molecules. 2024;29(2):545. Published 2024 Jan 22. [Content Brief]
[2]. Hu XY, et al. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Mol Oncol. 2019;13(2):246-263. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
LR004 関連分類
HY-P991969 関連分類
Powered by Bioz